468 related articles for article (PubMed ID: 9505058)
1. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
5. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
Mercier-Guyon C; Chabannes JP; Saviuc P
Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
Nguyen N; Fakra E; Pradel V; Jouve E; Alquier C; Le Guern ME; Micallef J; Blin O
Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
[TBL] [Abstract][Full Text] [Related]
7. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.
Diamond BI; Nguyen H; O'Neal E; Ochs R; Kaffeman M; Borison RL
Psychopharmacol Bull; 1991; 27(1):67-71. PubMed ID: 1677774
[TBL] [Abstract][Full Text] [Related]
9. Ipsapirone: evidence for efficacy in depression.
Heller AH; Beneke M; Kuemmel B; Spencer D; Kurtz NM
Psychopharmacol Bull; 1990; 26(2):219-22. PubMed ID: 1978372
[TBL] [Abstract][Full Text] [Related]
10. [alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo].
Hantouche EG; Guelfi JD; Comet D
Encephale; 1998; 24(5):469-79. PubMed ID: 9850822
[TBL] [Abstract][Full Text] [Related]
11. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
Cohn JB; Wilcox CS
J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
[TBL] [Abstract][Full Text] [Related]
12. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Reoux JP; Saxon AJ; Malte CA; Baer JS; Sloan KL
Alcohol Clin Exp Res; 2001 Sep; 25(9):1324-9. PubMed ID: 11584152
[TBL] [Abstract][Full Text] [Related]
13. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder.
Ballenger JC; McDonald S; Noyes R; Rickels K; Sussman N; Woods S; Patin J; Singer J
Psychopharmacol Bull; 1991; 27(2):171-9. PubMed ID: 1681563
[TBL] [Abstract][Full Text] [Related]
14. Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
Pinosky DG
J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):24-9. PubMed ID: 30763
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes.
Honderick T; Williams D; Seaberg D; Wears R
Am J Emerg Med; 2003 Jan; 21(1):39-42. PubMed ID: 12563578
[TBL] [Abstract][Full Text] [Related]
16. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety].
Lôo H; Malka R; Hantouche E; Lancrenon S; Guelfi JD
Encephale; 1991; 17(4):295-300. PubMed ID: 1959498
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
Fresquet A; Sust M; Lloret A; Murphy MF; Carter FJ; Campbell GM; Marion-Landais G
Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820
[TBL] [Abstract][Full Text] [Related]
18. Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Fabbrini M; Frittelli C; Bonanni E; Maestri M; Manca ML; Iudice A
Clin Ther; 2005 Jan; 27(1):78-83. PubMed ID: 15763608
[TBL] [Abstract][Full Text] [Related]
19. The effect of lorazepam on hypertension-associated anxiety: a double-blind study.
Hart WL; Parmley LF
J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):41-5. PubMed ID: 30767
[TBL] [Abstract][Full Text] [Related]
20. Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal.
Gerra G; Giucasto G; Zaimovic A; Fertonani G; Chittolini B; Avanzini P; Caccavari R; Delsignore R
Int Clin Psychopharmacol; 1996 Jun; 11(2):81-8. PubMed ID: 8803645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]